Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

CTI BioPharma ($CTIC) stock rallied as the company announced that the FDA has agreed to remove the full clinical hold on its myelofibrosis candidate pacritinib. The treatment was suspended from clinical development in February over safety concerns.
However, the company reported that it addressed all the issues with final results from two studies, PERSIST-1 and PERSIST-2. CTI BioPharma announced that it plans to commence a new trial PAC203 next quarter. The company is developing Pactritinib as a potential treatment for certain types of blood related cancers. The company stock closed over 26% in its previous trading session.

Ionis Pharmaceuticals ($IONS) stock slumped on the news of its failed mid-stage study assessing IONIS-DMPK-2.5rx. The treatment is being developed for the treatment of a rare genetic muscle wasting disorder called myotonic dystrophy type 1 (DM1).This type of dystrophy is caused by mutations in a gene called DMPK.
The study consisted of a small trial assessing five doses of IONIS-DMPK-2.5rx administered for six weeks. While the drug appeared to be safe and well-tolerated, the desired potency in muscle was not achieved. Ionis had recently announced encouraging results for its Phase 2 Study assessing IONIS-GCGRrx in patients suffering from type 2 diabetes.

 

• Bristol-Myers Squibb ($BMY) reported exercising its option to extend the research term for an additional 12 months under its immuno-oncology discovery, development and commercialization agreement with Five Prime Therapeutics ($FPRX). Under the revised deal, the company will provide additional research funding for the 12-month period ending March 2018.
• Amgen ($AMGN) reported that its competitor Regeneron ($REGN) has been ordered to withdraw its cholesterol drug from the market as a penalty in a patent lawsuit. The company plans to appeal the injunction.

• Heron Therapeutics ($HRTX) announced positive results from two Phase 2 clinical trials, Study 203 and Study 208, assessing HTX-011 for the management of post-operative pain following abdominoplasty.
• BioPharmX ($BPMX) announced hitting the enrollment target in its Phase 2 clinical trial, OPAL, assessing BPX-01 for the treatment of moderate-to-severe inflammatory, non-nodular acne vulgaris. The primary endpoint is the absolute mean change from baseline in inflammatory lesion count at week 12.

 
• Mazor Robotics ($MZOR) announced that it booked 21 orders for its systems last quarter. The company said that its backlog stands at 21 systems, including six to be delivered to investor/distributor Medtronic ($MDT).
• Pieris Pharmaceuticals ($PIRS) announced a co-development alliance with Servier in immuno-oncology. The companies will jointly engage in several bispecific therapeutic programs including Pieris' dual checkpoint inhibitor PRS-332 as well as four additional programs.

 
• AngioDynamics ($ANGO) reported its EPS for the second quarter at $0.19, beating consensus estimates by $0.03. its revenue declined 0.3% on year over year basis to $89.03 million.

• Kite Pharma ($KITE) receives initial rating of Buy from Roth Capital. The price target for the stock has been set at $68.
• Achaogen ($AKAO) receives initial rating of Outperform from Leerink Swann. The price target for the stock has been set at $21.

Gainers (% price change) Last Trade Change Mkt Cap
CTI BioPharma Corp
CTIC (NASDAQ)
4.46 +0.49 (12.34%) 127.19M
CyberOptics Corporation
CYBE (NASDAQ)
30.15 +2.70 (9.84%) 212.94M
Alexion Pharmaceuticals
ALXN (NASDAQ)
139.18 +12.07 (9.50%) 32.35B
Endologix, Inc.
ELGX (NASDAQ)
6.19 +0.41 (7.09%) 536.94M
Pacific Biosciences of
PACB (NASDAQ)
4.81 +0.22 (4.79%) 469.14M
Losers (% price change)
Pacira Pharmaceuticals
PCRX (NASDAQ)
34.15 -2.60 (-7.07%) 1.35B
Curis, Inc.
CRIS (NASDAQ)
3.12 -0.21 (-6.31%) 450.69M
ImmunoGen, Inc.
IMGN (NASDAQ)
2.37 -0.12 (-4.82%) 247.69M
Dynavax Tech. Corp.
DVAX (NASDAQ)
4.20 -0.20 (-4.55%) 175.80M
Rigel Pharmaceuticals
RIGL (NASDAQ)
2.46 -0.11 (-4.28%) 251.21M
Most Actives (dollar volume)
Alexion Pharmaceuticals
ALXN (NASDAQ)
139.18 +12.07 (9.50%) 32.35B
Gilead Sciences, Inc.
GILD (NASDAQ)
76.01 -0.37 (-0.48%) 103.14B
Pfizer Inc.
PFE (NYSE)
33.61 +0.32 (0.96%) 205.75B
Johnson & Johnson
JNJ (NYSE)
116.86 +1.21 (1.05%) 317.40B
Merck & Co., Inc.
MRK (NYSE)
60.11 -0.02 (-0.03%) 165.68B